InteKrin's INT131 meets diabetes endpoint

InteKrin Therapeutics Inc. (Los Altos, Calif.) reported that oral INT131 met the primary endpoint of significantly decreasing HbA1c from baseline vs. placebo at 24 weeks in the Phase IIb INT131-007 trial to treat Type II diabetes (p<0.0001). InteKrin said INT131's efficacy was "comparable" to that shown by active-comparator Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). InteKrin also said INT131 showed a superior side effect profile compared with Actos. The double-blind, U.S. and Mexican trial enrolled 366 patients. InteKrin plans to start Phase III testing in 2Q10. ...